Do analysts recommend IMMP or TPST?

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,314.25%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Prima BioMed is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, IMMP or TPST?

Tempest Therapeutics has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.57 -$39.78M N/A N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is IMMP or TPST more profitable?

Prima BioMed's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Tempest Therapeutics N/A -355.61% -121.21%

Do analysts recommend CNTX or TPST?

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 905.33%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, CNTX or TPST?

Context Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is CNTX or TPST more profitable?

Context Therapeutics' return on equity of -59.95% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Tempest Therapeutics N/A -355.61% -121.21%

Does the media favor CNTX or TPST?

In the previous week, Context Therapeutics and Context Therapeutics both had 3 articles in the media. Context Therapeutics' average media sentiment score of 1.27 beat Tempest Therapeutics' score of 0.80 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TPST or XLO?

Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 230.19%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate TPST or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% BeyondSpring N/A N/A -14.00%

Do analysts prefer MCRB or TPST?

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 221.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is MCRB or TPST more profitable?

Seres Therapeutics' return on equity of -130.29% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Tempest Therapeutics N/A -355.61% -121.21%

Tempest Therapeutics (TPST) Competitors

$0.95 -0.04 (-3.95%)

Closing price 04:00 PM Eastern

Extended Trading

$0.99 +0.04 (+3.98%)

As of 04:23 PM Eastern

Compare

TPST vs. IMMP, CNTX, XLO, BYSI, and MCRB

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include Prima BioMed (IMMP), Context Therapeutics (CNTX), Xilio Therapeutics (XLO), BeyondSpring (BYSI), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Tempest Therapeutics has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.57	-$39.78M	N/A	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Prima BioMed's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Tempest Therapeutics	N/A	-355.61%	-121.21%

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,314.25%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Prima BioMed is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tempest Therapeutics had 3 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for Prima BioMed. Tempest Therapeutics' average media sentiment score of 0.80 beat Prima BioMed's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Prima BioMed	Neutral
Tempest Therapeutics	Positive

Prima BioMed has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, indicating that its stock price is 273% less volatile than the broader market.

Summary

Prima BioMed beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Context Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, indicating that its share price is 273% less volatile than the broader market.

Context Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 905.33%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Context Therapeutics' return on equity of -59.95% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Tempest Therapeutics	N/A	-355.61%	-121.21%

In the previous week, Context Therapeutics and Context Therapeutics both had 3 articles in the media. Context Therapeutics' average media sentiment score of 1.27 beat Tempest Therapeutics' score of 0.80 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Context Therapeutics beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Xilio Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 230.19%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Tempest Therapeutics had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for Xilio Therapeutics. Tempest Therapeutics' average media sentiment score of 0.80 beat Xilio Therapeutics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
Xilio Therapeutics	Neutral

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tempest Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Xilio Therapeutics	$53.48M	1.04	-$35.04M	-$3.55	N/A

Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Summary

Xilio Therapeutics beats Tempest Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to BeyondSpring?

Tempest Therapeutics (NASDAQ:TPST) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tempest Therapeutics had 3 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for BeyondSpring. Tempest Therapeutics' average media sentiment score of 0.80 beat BeyondSpring's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
BeyondSpring	Neutral

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeyondSpring has higher revenue and earnings than Tempest Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
BeyondSpring	$1.75M	26.55	-$1.01M	-$0.14	N/A

Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
BeyondSpring	N/A	N/A	-14.00%

Summary

BeyondSpring beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Seres Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market.

In the previous week, Tempest Therapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for Seres Therapeutics. Tempest Therapeutics' average media sentiment score of 0.80 beat Seres Therapeutics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Tempest Therapeutics	Positive

Seres Therapeutics' return on equity of -130.29% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Seres Therapeutics has higher revenue and earnings than Tempest Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	64.70	$5.70M	-$5.17	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 221.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.20M	$3.05B	$6.77B	$12.60B
Dividend Yield	N/A	2.05%	2.67%	9.67%
P/E Ratio	-0.16	19.84	26.91	23.97
Price / Sales	N/A	482.76	507.72	91.38
Price / Cash	N/A	27.72	49.71	59.37
Price / Book	0.70	4.21	10.56	6.16
Net Income	-$26.26M	$65.94M	$3.60B	$331.71M
7 Day Performance	-11.11%	-2.81%	-2.15%	-1.94%
1 Month Performance	-23.91%	-1.44%	0.11%	-2.49%
1 Year Performance	-84.93%	15.55%	22.63%	17.28%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.4364 of 5 stars	$0.95 -3.9%	N/A	-84.4%	$15.20M	N/A	N/A	20	News Coverage
IMMP Prima BioMed	2.0369 of 5 stars	$0.45 +7.5%	$5.50 +1,120.9%	-76.6%	$61.75M	$6.69M	N/A	2,021	Gap Down
CNTX Context Therapeutics	3.0432 of 5 stars	$0.62 -4.5%	$6.17 +888.6%	-27.5%	$59.99M	N/A	N/A	7	Positive News Analyst Downgrade
XLO Xilio Therapeutics	1.933 of 5 stars	$9.24 +1.5%	$28.00 +203.0%	-10.9%	$59.83M	$43.77M	N/A	70	Gap Up
BYSI BeyondSpring	0.0293 of 5 stars	$1.33 -7.6%	N/A	-33.5%	$59.21M	$1.75M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. IMMP, CNTX, XLO, BYSI, and MCRB

How does Tempest Therapeutics compare to Prima BioMed?

Summary

How does Tempest Therapeutics compare to Context Therapeutics?

Summary

How does Tempest Therapeutics compare to Xilio Therapeutics?

Summary

How does Tempest Therapeutics compare to BeyondSpring?

Summary

How does Tempest Therapeutics compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. IMMP, CNTX, XLO, BYSI, and MCRB

How does Tempest Therapeutics compare to Prima BioMed?

Which has better earnings and valuation, IMMP or TPST?

Is IMMP or TPST more profitable?

Do analysts recommend IMMP or TPST?

Do insiders and institutionals have more ownership in IMMP or TPST?

Does the media favor IMMP or TPST?

Which has more volatility and risk, IMMP or TPST?

Summary

How does Tempest Therapeutics compare to Context Therapeutics?

Which has more risk & volatility, CNTX or TPST?

Which has preferable valuation and earnings, CNTX or TPST?

Do analysts recommend CNTX or TPST?

Is CNTX or TPST more profitable?

Does the media favor CNTX or TPST?

Do institutionals & insiders hold more shares of CNTX or TPST?

Summary

How does Tempest Therapeutics compare to Xilio Therapeutics?

Do analysts rate TPST or XLO?

Does the media refer more to TPST or XLO?

Do institutionals and insiders hold more shares of TPST or XLO?

Which has better valuation and earnings, TPST or XLO?

Which has more risk & volatility, TPST or XLO?

Is TPST or XLO more profitable?

Summary

How does Tempest Therapeutics compare to BeyondSpring?

Do analysts rate TPST or BYSI?

Does the media refer more to TPST or BYSI?

Do institutionals and insiders hold more shares of TPST or BYSI?

Which has better valuation and earnings, TPST or BYSI?

Which has more risk & volatility, TPST or BYSI?

Is TPST or BYSI more profitable?

Summary

How does Tempest Therapeutics compare to Seres Therapeutics?

Which has more volatility & risk, MCRB or TPST?

Does the media prefer MCRB or TPST?

Is MCRB or TPST more profitable?

Which has stronger earnings and valuation, MCRB or TPST?

Do analysts prefer MCRB or TPST?

Do insiders & institutionals have more ownership in MCRB or TPST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools